Table 1 Demography and spirometry data of the recruited subjects
From: Th17 cytokines induce pro-fibrotic cytokines release from human eosinophils
Asthmatics | Healthy controls | |
|---|---|---|
Age (years) | 33.3 ± 2.6 | 38.2 ± 3.4 |
Males/females | 6/4 | 6/4 |
Atopy (% of total) | 100% | 0 |
Duration of disease (years) | 16.5 ± 9.8 | n/a |
Peripheral Blood Eosinophls | 0.78 ± 0.04×109/l | 0.31 ± 0.02×109/l |
FEV1 (mean ± SD) | 57.73 ± 2.56 | 107.5 ± 5.63 |
FVC (mean ± SD) | 75.14 ±3.27 | 104.6 ± 6.87 |
FEV/FVC (mean ± SD) | 66.34 ± 5.39 | 83 ± 4.62 |
Medications | - Inhaled corticosteroids: Symbicort II (Budesonide/Formoterol) (160/4.5 ug) (1–2 inhalations twice daily). | No |
- Anti-leukotriene: Singulair (montelukast sodium) (10 mg/d). | ||
- Ventolin (albuterol) (as needed). |